The Influence of GPX1 Pro198Leu, CAT C262T and MnSOD Ala16Val Gene Polymorphisms on Susceptibility for Non-Hodgkin Lymphoma and Overall Survival Rate at Five Years from Diagnosis

: The aim of the current study was to investigate possible associations between catalase C262T ( C262T), glutathione peroxidase 1 Pro198Leu ( Pro198Leu), manganese superoxide dismutase Ala16Val ( Ala16Val) gene polymorphisms and non-Hodgkin Lymphoma risk (NHL) in a Romanian population and the five-y...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta Medica Marisiensis 2019-03, Vol.65 (1), p.25-30
Hauptverfasser: Cosma, Adriana-Stela, Radu, Cristina, Moldovan, Alexandra, Bogliș, Alina, Crauciuc, George Andrei, Horváth, Emőke, Cândea, Marcela, Tripon, Florin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:: The aim of the current study was to investigate possible associations between catalase C262T ( C262T), glutathione peroxidase 1 Pro198Leu ( Pro198Leu), manganese superoxide dismutase Ala16Val ( Ala16Val) gene polymorphisms and non-Hodgkin Lymphoma risk (NHL) in a Romanian population and the five-year overall survival rate of the NHL patients. : We included in this case-control study 406 individuals, divided into two groups: the control group (n=315) and the patients group (n=91). The DNA was extracted from peripheral blood and amplified using specific techniques. : The variant homozygous genotype of Pro198Leu represents a risk factor for NHL development and no associations regarding the risk for NHL were found for Ala16Val and C262T gene polymorphisms. Two of the studied polymorphisms were associated with the overall survival rate thus: negative association regarding Ala16Val, associated with higher overall survival rate and a positive one regarding C262T, associated with lower overall survival rate. : According to our results, the mentioned polymorphisms may be considered as susceptible markers of the five-year overall survival rate for NHL patients. Future studies with a larger number of patients are needed to confirm our results.
ISSN:2247-6113
2068-3324
2247-6113
DOI:10.2478/amma-2019-0005